Program
bomedemstat
Also written as “Bomedemstat”.
Its studies are mostly in Thrombocythemia, Essential · Polycythemia Vera · Hepatic Insufficiency · Primary Myelofibrosis · Leukemia, Myeloid, Acute, led by Merck.
Furthest: phase 3, since Oct 6, 202311 company-led studies, 4 open or runningNext primary completion: Jul 14, 2027 (phase 3)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Merck | 114 open or running | phase 3since Oct 6, 2023 | Jul 12, 2016 | Jul 14, 2027phase 3 · NCT06079879 |
- Named in Merck’s own pipeline as
bomedemstat (MK-3543)
, phase 3, as of Nov 2, 2026 (source).
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Jul 12, 2016First study: phase 2 study in Leukemia, Myeloid, AcuteFirst studyNCT02842827 · 45 enrolled · Australia
- Apr 18, 2017Phase 2 study in Primary MyelofibrosisNCT03136185 · 90 enrolled · United States, Australia, Germany and more
- Jan 15, 2020Phase 2 study in Thrombocythemia, EssentialNCT04254978 · 73 enrolled · United States, Australia, Germany and more
- Aug 31, 2021Phase 2 study in Thrombocythemia, EssentialNCT05223920 · 81 enrolled · United States, Australia, Germany and more
- Sep 20, 2022Phase 2 study in Polycythemia VeraNCT05558696 · 20 enrolled · United States, Australia, United Kingdom
- Oct 6, 2023Phase 3 study in Thrombocythemia, EssentialNCT06079879 · 340 enrolled · United States, Argentina, Australia and more
- Apr 2, 2024Phase 3 study in Thrombocythemia, EssentialNCT06351631 · 400 planned · United States, Australia, Hong Kong and more
- Jun 7, 2024Phase 3 study in Thrombocythemia, EssentialNCT06456346 · 300 enrolled · United States, Argentina, Australia and more
- Sep 11, 2024Phase 1 study in HealthyNCT06596668 · 16 enrolled · United States
- Jun 25, 2025Phase 1 study in Hepatic InsufficiencyNCT07049939 · 9 enrolled · United States
- Jul 20, 2026Phase 3 study in Polycythemia VeraNCT07722611 · 380 planned · United States, Canada, Israel
Ahead
- Jul 14, 2027Primary completion: phase 3 study in Thrombocythemia, EssentialNCT06079879
- Sep 28, 2027Primary completion: phase 3 study in Thrombocythemia, EssentialNCT06456346
- Jun 25, 2032Primary completion: phase 3 study in Polycythemia VeraNCT07722611
- Dec 4, 2034Primary completion: phase 3 study in Thrombocythemia, EssentialNCT06351631
TargetBeta
“An orally available, irreversible inhibitor of lysine-specific demethylase 1 (LSD1), with potential antineoplastic activity. Upon administration, bomedemstat binds to and inhibits LSD1, a demethylase that suppresses the expression of target genes by converting the di- and mono-methylated forms of…”NCIt, read by Claude
“An orally available, irreversible inhibitor of lysine-specific demethylase 1 (LSD1), ”NCIt, by rule
“Lysine-specific histone demethylase 1 inhibitor”ChEMBL 37, by rule
Other programs on KDM1A
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| LSD1 Inhibitor EXS74539rule | exscientia-ai-ltd-a-wholly-owned-subsidiary-of-recursion-pha | phase 1 | 1 |
Studies
All 11 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07722611Polycythemia Vera · United States, Canada, Israel | 3 | Recruiting | Jun 25, 2032 | 380 |
| NCT07049939Hepatic Insufficiency · United States | 1 | Completed | Feb 17, 2026 | 9 |
| NCT06596668Healthy · United States | 1 | Completed | Feb 5, 2025 | 16 |
| NCT06456346Thrombocythemia, Essential · United States, Argentina, Australia and more | 3 | Active, not recruiting | Sep 28, 2027 | 300 |
| NCT06351631Thrombocythemia, Essential · United States, Australia, Hong Kong and more | 3 | Recruiting | Dec 4, 2034 | 400 |
| NCT06079879Thrombocythemia, Essential · United States, Argentina, Australia and more | 3 | Active, not recruiting | Jul 14, 2027 | 340 |
| NCT05558696Polycythemia Vera · United States, Australia, United Kingdom | 2 | Completed | Mar 24, 2025 | 20 |
| NCT05223920Thrombocythemia, Essential · United States, Australia, Germany and more | 2 | Completed | Aug 22, 2024 | 81 |
| NCT04254978Thrombocythemia, Essential · United States, Australia, Germany and more | 2 | Completed | Mar 23, 2023 | 73 |
| NCT03136185Primary Myelofibrosis · United States, Australia, Germany and more | 2 | Completed | Mar 8, 2022 | 90 |
| NCT02842827Leukemia, Myeloid, Acute · Australia | 2 | Completed | Oct 30, 2018 | 45 |
How it is read
Names in the registry
- “Bomedemstat”, 9 entries
- “bomedemstat”, 2 entries
Conditions, from the studies’ own filings
- Thrombocythemia, Essential, 5 studies
- Polycythemia Vera, 2 studies
- Hepatic Insufficiency, 1 study
- Primary Myelofibrosis, 1 study
- Leukemia, Myeloid, Acute, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.